GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » ROC (Joel Greenblatt) %

Sunho Biologics (HKSE:02898) ROC (Joel Greenblatt) % : -122.74% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sunho Biologics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -122.74%.

The historical rank and industry rank for Sunho Biologics's ROC (Joel Greenblatt) % or its related term are showing as below:

HKSE:02898' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -269.38   Med: -185.43   Max: -101.48
Current: -185.58

During the past 2 years, Sunho Biologics's highest ROC (Joel Greenblatt) % was -101.48%. The lowest was -269.38%. And the median was -185.43%.

HKSE:02898's ROC (Joel Greenblatt) % is ranked better than
57.2% of 1402 companies
in the Biotechnology industry
Industry Median: -310.545 vs HKSE:02898: -185.58

Sunho Biologics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Sunho Biologics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Sunho Biologics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics ROC (Joel Greenblatt) % Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23
ROC (Joel Greenblatt) %
-101.48 -269.38

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
ROC (Joel Greenblatt) % - -259.62 -278.46 -122.74

Competitive Comparison of Sunho Biologics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Sunho Biologics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunho Biologics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's ROC (Joel Greenblatt) % falls into.


';

Sunho Biologics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.895 + 16.371) - (69.3 + 0 + 352.336)
=-404.37

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 1.095 + 14.211) - (3.828 + 0 + 6.473)
=5.005

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Sunho Biologics for the quarter that ended in Jun. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-76.458/( ( (55.574 + max(-404.37, 0)) + (64.01 + max(5.005, 0)) )/ 2 )
=-76.458/( ( 55.574 + 69.015 )/ 2 )
=-76.458/62.2945
=-122.74 %

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunho Biologics  (HKSE:02898) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Sunho Biologics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines